Ultragenyx Pharmaceutical
RARE
310 hedge funds and large institutions have $3.55B invested in Ultragenyx Pharmaceutical in 2026 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 115 increasing their positions, 98 reducing their positions, and 44 closing their positions.
73% more capital invested
Capital invested by funds: $2.05B → $3.55B (+$1.5B)
34% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 44
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
17% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 98
6.75% more ownership
Funds ownership: 101.57% → 108.33% (+6.8%)
4% more funds holding
Funds holding: 298 → 310 (+12)
17% less call options, than puts
Call options by funds: $57.5M | Put options by funds: $69.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$103M |
| 2 |
BlackRock
New York
|
+$83.3M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$49.3M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$37.5M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$35.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$53.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$47.3M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$35.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$34.5M |
| 5 |
Millennium Management
New York
|
-$25.1M |
RARE Hedge Fund Activity: Q2 2026 in Review
310 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2026, worth a combined $3.55B — up 73% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new RARE positions and 44 closed out — a net gain of 15 holders — while 115 added to existing stakes and 98 trimmed.
The largest buyer was RTW Investments, adding an estimated $103M. The largest seller was Assenagon Asset Management, cutting an estimated $53.1M.
- 310 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2026, up from 298 in Q1 2026.
- Funds reported $3.55B of Ultragenyx Pharmaceutical stock for Q2 2026, up 73% quarter-over-quarter.
- 59 funds opened new Ultragenyx Pharmaceutical positions in Q2 2026 and 44 closed out, a net change of +15 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2026 was RTW Investments, an estimated $103M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2026 was Assenagon Asset Management, an estimated $53.1M sold.
Based on aggregated 13F filings for Q2 2026.